BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 32242310)

  • 21. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
    Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
    Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
    Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
    Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma.
    Chipps BE; Hirsch I; Trudo F; Alacqua M; Zangrilli JG
    Ann Allergy Asthma Immunol; 2020 Jan; 124(1):79-86. PubMed ID: 31626906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years.
    Korn S; Bourdin A; Chupp G; Cosio BG; Arbetter D; Shah M; Gil EG
    J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4381-4392.e4. PubMed ID: 34487870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma.
    Dávila González I; Moreno Benítez F; Quirce S
    J Investig Allergol Clin Immunol; 2019 Apr; 29(2):84-93. PubMed ID: 31017107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological therapies for eosinophilic asthma.
    Patel SS; Casale TB; Cardet JC
    Expert Opin Biol Ther; 2018 Jul; 18(7):747-754. PubMed ID: 29938543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benralizumab for the treatment of asthma.
    Saco TV; Pepper AN; Lockey RF
    Expert Rev Clin Immunol; 2017 May; 13(5):405-413. PubMed ID: 28379047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
    Busse W; Chupp G; Nagase H; Albers FC; Doyle S; Shen Q; Bratton DJ; Gunsoy NB
    J Allergy Clin Immunol; 2019 Jan; 143(1):190-200.e20. PubMed ID: 30205189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma.
    Bourdin A; Shaw D; Menzies-Gow A; FitzGerald JM; Bleecker ER; Busse WW; Ferguson GT; Brooks L; Barker P; Gil EG; Martin UJ
    J Asthma; 2021 Apr; 58(4):514-522. PubMed ID: 31859541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction/elimination of blood eosinophils in severe asthma: should there be a safety consideration?
    Katsoulis K; Kipourou M; Loukides S
    Expert Opin Biol Ther; 2022 Mar; 22(3):377-384. PubMed ID: 34328380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment.
    Busse WW; Bleecker ER; FitzGerald JM; Ferguson GT; Barker P; Brooks L; Olsson RF; Martin UJ; Goldman M;
    J Allergy Clin Immunol; 2021 Jul; 148(1):266-271.e2. PubMed ID: 33609624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reductions in eosinophil biomarkers by benralizumab in patients with asthma.
    Pham TH; Damera G; Newbold P; Ranade K
    Respir Med; 2016 Feb; 111():21-9. PubMed ID: 26775606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.
    Al Efraij K; FitzGerald JM
    Expert Rev Clin Pharmacol; 2018 Jul; 11(7):669-676. PubMed ID: 29972739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benralizumab for the treatment of asthma.
    Matera MG; Rogliani P; Calzetta L; Canonica GW; Cazzola M
    Drugs Today (Barc); 2017 Dec; 53(12):633-645. PubMed ID: 29517082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of treatment with benralizumab for eosinophilic asthma.
    Zhu M; Yang J; Chen Y
    Int Immunopharmacol; 2022 Oct; 111():109131. PubMed ID: 35998507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects.
    Máspero J
    Ther Adv Respir Dis; 2017 Aug; 11(8):311-325. PubMed ID: 28683596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long-term safety (TATE study).
    Wedner HJ; Fujisawa T; Guilbert TW; Ikeda M; Mehta V; Tam JS; Lukka PB; Asimus S; Durżyński T; Johnston J; White WI; Shah M; Werkström V; Jison ML;
    Pediatr Allergy Immunol; 2024 Mar; 35(3):e14092. PubMed ID: 38491795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
    Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
    Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies.
    Criner GJ; Celli BR; Singh D; Agusti A; Papi A; Jison M; Makulova N; Shih VH; Brooks L; Barker P; Martin UJ; Newbold P
    Lancet Respir Med; 2020 Feb; 8(2):158-170. PubMed ID: 31575508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.